JointStem
-
East Asia
Success of JointStem Phase 3 Clinical Trial, world’s first adipose tissue derived mesenchymal stem cell treatment for osteoarthritis of the knee
-Successful data for the reduction of pain and the improvement of knee cartilage function in severe osteoarthritis (OA) patients with Kellgren and Lawrence (K-L) grade 3 -The outcome of Korean stem cell research and development of 16 years and the results of hard work including tens of millions of dollars…
Read More » -
Society
Nature Cell announces Phase 3 clinical trials results of “JointStem,”, world’s first treatment for severe degenerative arthritis
Retain statistical significance for both joint function and pain as the primary evaluation index Based upon the ‘P’ value that determines the success or failure of statistical significance, results were far better than 0.05 point By Juhyung Lee, Reporter mintcondition@theasian.asia SEOUL: On March 15, Nature Cell, the South Korean stem…
Read More » -
IT-Science
Deep commitment to serving humanity highlighted
SEOUL: 경천애인(Gyeongcheon-Aein) and 진천사대천명(Jincheonsa-Daecheonmyung). These are words that Dr. Ra Jung-chan, CEO of Nature Cell, always keeps in mind. It means “I respect God and love my neighbor like my own body,” and “I wait for heaven’s help after doing my best for the work that God has called me…
Read More » -
East Asia
FDA approves JointStem, an arthritis-specialized stem cell therapy
By The AsiaN Editor SEOUL: JointStem, the world’s first self-fat-derived mid-leaf cell treatment for severe degenerative arthritis, has passed the U.S. Food and Drug Administration’s commercial clinical 2b/3a review, Nature Cell Co has announced. This provides a meaningful opportunity to open the era of treating U.S. patients with Korean stem…
Read More »